Ditch the painkillers! While they can provide temporary relief, there are other ways to numb pain without medication. Find ...

JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. This press release features multimedia.

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.

In his early 20s, Pope Francis underwent surgery to remove a part of his lung affected by a severe respiratory infection.

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...